4.8 Article

Sox4 Is a Key Oncogenic Target in C/EBPα Mutant Acute Myeloid Leukemia

Journal

CANCER CELL
Volume 24, Issue 5, Pages 575-588

Publisher

CELL PRESS
DOI: 10.1016/j.ccr.2013.09.018

Keywords

-

Funding

  1. National Institutes of Health [HL 56745, CA118316, NIH/NIAMS R01 AR54153]
  2. Harvard Stem Cell Institute [DP-0086-10-00]
  3. Navrat grant from the Czech Ministry of Youth, Health and Sports [LK21307]
  4. Collegio Ghislieri fellowship
  5. Austrian Research Foundation
  6. European Union
  7. Societa' Italiana di Ematologia Sperimentale borsa di studio
  8. Jose Carreras Leukemia Foundation [FIJC F11/01]
  9. FAMRI CIA
  10. Leukaemia Lymphoma Research
  11. Medical Research Council [G0902418, G0900892] Funding Source: researchfish
  12. MRC [G0902418, G0900892] Funding Source: UKRI

Ask authors/readers for more resources

Mutation or epigenetic silencing of the transcription factor C/EBP alpha is observed in similar to 10% of patients with acute myeloid leukemia (AML). In both cases, a common global gene expression profile is observed, but downstream targets relevant for leukemogenesis are not known. Here, we identify Sox4 as a direct target of C/EBP alpha whereby its expression is inversely correlated with C/EBP alpha activity. Downregulation of Sox4 abrogated increased self-renewal of leukemic cells and restored their differentiation. Gene expression profiles of leukemia-initiating cells (LICs) from both Sox4 overexpression and murine C/EBP alpha mutant AML models clustered together but differed from other types of AML. Our data demonstrate that Sox4 overexpression resulting from C/EBP alpha inactivation contributes to the development of leukemia with a distinct LIC phenotype.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available